Private Client Services LLC Acquires Shares of 6,411 Illumina, Inc. $ILMN

Private Client Services LLC purchased a new position in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,411 shares of the life sciences company’s stock, valued at approximately $841,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Board of the Pension Protection Fund bought a new stake in Illumina during the fourth quarter worth about $26,000. Quent Capital LLC bought a new stake in shares of Illumina during the 3rd quarter worth approximately $29,000. Quarry LP acquired a new stake in shares of Illumina during the 3rd quarter worth approximately $32,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Illumina during the 3rd quarter worth $33,000. Finally, Strategic Advocates LLC acquired a new stake in Illumina in the third quarter valued at about $44,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ILMN. Canaccord Genuity Group boosted their target price on Illumina from $130.00 to $150.00 and gave the stock a “hold” rating in a research note on Monday, January 26th. Evercore set a $150.00 price target on shares of Illumina in a research note on Friday, February 6th. Wall Street Zen raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 14th. Stifel Nicolaus increased their price target on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, Robert W. Baird set a $137.00 price objective on Illumina in a report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $129.69.

Illumina Trading Down 1.8%

NASDAQ:ILMN opened at $124.33 on Friday. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $155.53. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.72 and a current ratio of 2.08. The firm’s fifty day moving average is $130.92 and its 200-day moving average is $120.62. The firm has a market cap of $19.01 billion, a P/E ratio of 22.81, a P/E/G ratio of 2.42 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.10 billion. Illumina had a net margin of 19.57% and a return on equity of 31.04%. Illumina’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 earnings per share. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Insider Activity

In other news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the transaction, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.60% of the stock is owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.